Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of elafibranor in patients with non-alcoholic steatohepatitis (NASH) and fibrosis
2015-005385-38Phase 3Terminated
- Sponsor
- Genfit
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis comparing Elafibranor with Placebo (2 arms). Primary endpoint: Primary endpoint (surrogate endpoint). Started Jan 2016; status: terminated.
02
Drugs
elafibranor
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on 2015-005385-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005385-38.